ideasIdea
A dedicated clinic for people whose blood test says the cancer is back
A positive leftover-cancer blood test leaves patients frightened and their doctors unsure what to do. A specialist clinic could give them a plan and a trial.
The molecular relapse population is growing fast and falls between services: no visible disease, no standard therapy, high anxiety and low trial awareness. A named clinic — confirmatory retesting, sensitive imaging, psychological support, trial screening and structured follow-up — is a service-design intervention that could be evaluated like any other pathway.
Hypothesis
A dedicated molecular relapse clinic increases trial enrolment among ctDNA-positive patients threefold and reduces anxiety scores compared with usual follow-up, with no increase in cost per patient once inappropriate imaging is avoided.
Rationale
Analogous focused services — rapid diagnostic centres, cancer of unknown primary clinics, cardio-oncology — improved both pathway metrics and enrolment. The bottleneck for MRD trials is not eligibility but the absence of anyone whose job it is to act on the result.
What would test it
Two-centre service pilot with pre-specified metrics: time from positive result to plan, trial enrolment rate, imaging use, patient-reported anxiety at three months.
Maturity
speculative
Who has to act
clinic
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Patients lack understanding, navigation and agency · Most patients cannot understand their options, find trials, or push back, so decisions are made for them.